학술논문

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Document Type
article
Author
Köbel, MartinKang, Eun‐YoungWeir, AshleyRambau, Peter FLee, Cheng‐HanNelson, Gregg SGhatage, PrafullMeagher, Nicola SRiggan, Marjorie JAlsop, JenniferAnglesio, Michael SBeckmann, Matthias WBisinotto, ChristianiBoisen, MichelleBoros, JessicaBrand, Alison HBrooks‐Wilson, AngelaCarney, Michael ECoulson, PennyCourtney‐Brooks, MadeleineCushing‐Haugen, Kara LCybulski, CezaryDeen, SuhaEl‐Bahrawy, Mona AElishaev, EstherErber, RamonaFereday, SianGroup, AOCSFischer, AnnaGayther, Simon ABarquin‐Garcia, ArantzazuGentry‐Maharaj, AleksandraGilks, C BlakeGronwald, HelenaGrube, MarcelHarnett, Paul RHarris, Holly RHartkopf, Andreas DHartmann, ArndtHein, AlexanderHendley, JoyHernandez, Brenda YHuang, YajueJakubowska, AnnaJimenez‐Linan, MercedesJones, Michael EKennedy, Catherine JKluz, TomaszKoziak, Jennifer MLesnock, JaimeLester, JennyLubiński, JanLongacre, Teri ALycke, MariaMateoiu, ConstantinaMcCauley, Bryan MMcGuire, ValerieNey, BrittaOlawaiye, AlexanderOrsulic, SandraOsorio, AnaPaz‐Ares, LuisRamón y Cajal, TeresaRothstein, Joseph HRuebner, MatthiasSchoemaker, Minouk JShah, MitulSharma, RaghwaSherman, Mark EShvetsov, Yurii BSingh, NaveenaSteed, HelenStorr, Sarah JTalhouk, AlineTraficante, NadiaWang, ChenWhittemore, Alice SWidschwendter, MartinWilkens, Lynne RWinham, Stacey JBenitez, JavierBerchuck, AndrewBowtell, David Ddos Reis, Francisco J CandidoCampbell, IanCook, Linda SDeFazio, AnnaDoherty, Jennifer AFasching, Peter AFortner, Renée TGarcía, María JGoodman, Marc TGoode, Ellen LGronwald, JacekHuntsman, David GKarlan, Beth YKelemen, Linda EKommoss, StefanLe, Nhu DMartin, Stewart G
Source
The Journal of Pathology Clinical Research. 9(3)
Subject
Reproductive Medicine
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Cancer
Rare Diseases
Ovarian Cancer
Clinical Research
Aetiology
2.1 Biological and endogenous factors
Humans
Female
Tumor Suppressor Protein p53
Ovarian Neoplasms
Carcinoma
Ovarian Epithelial
Carcinoma
Endometrioid
ovarian cancer
high-grade serous carcinoma
endometrioid
clear cell
TP53
p53
prognosis
AOCS Group
Clinical sciences
Language
Abstract
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.